Cargando…
Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
Locally advanced or metastatic urothelial bladder cancer (a/m UBC) is currently treated using platinum-based combination chemotherapy. Immune checkpoint inhibitors (ICIs) are the preferred second-line treatment options for cisplatin-eligible a/m UBC patients and as first-line options in cisplatin-in...
Autores principales: | Lee, Hye Won, Seo, Ho Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431699/ https://www.ncbi.nlm.nih.gov/pubmed/34502435 http://dx.doi.org/10.3390/ijms22179526 |
Ejemplares similares
-
Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology
por: Choi, Hae Woong, et al.
Publicado: (2021) -
Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment
por: Chen, Ji, et al.
Publicado: (2022) -
Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma
por: Xu, Chaojie, et al.
Publicado: (2022) -
A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder
por: Feng, Huan, et al.
Publicado: (2023) -
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
por: Sternberg, Cora N., et al.
Publicado: (2022)